Correlation between CD8+ T cells specific for prostate-specific antigen and level of disease in patients with prostate cancer

Clinical Immunology

Volumn 120, Issue 1, 2006, Pages 91-98

  Elkord, Eyad ^a   Rowbottom, Anthony W ^b   Kynaston, Howard ^b   Williams, Paul E ^a,b  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

Author keywords

CD8+ T cells; Circulating PSA expressing cells (CPECs); Prostate cancer; Prostate specific antigen (PSA); Tetramer

Indexed keywords

HLA A2 ANTIGEN; MESSENGER RNA; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE; TETRAMER;

ACCURACY; ANALYTIC METHOD; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; CD8+ T LYMPHOCYTE; CELL SPECIFICITY; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; EPITHELIUM CELL; HUMAN; HUMAN CELL; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TESTOSTERONE BLOOD LEVEL;

CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; EPITHELIAL CELLS; HLA-A2 ANTIGEN; HUMANS; IMMUNOMAGNETIC SEPARATION; K562 CELLS; MALE; NEOPLASM CIRCULATING CELLS; PEPTIDE FRAGMENTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM; STATISTICS, NONPARAMETRIC; TESTOSTERONE;

EID: 33745149378     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2005.12.008     Document Type: Article

References (20)

1. Parkin D.M., Laara E., and Muir C.S. Estimates of the worldwide frequency of sixteen major cancers in 1980. Int. J. Cancer 41 (1988) 184-197
2. Parker S.L., Tong T., Bolden S., and Wingo P.A. Cancer statistics, 1996, CA. Cancer J. Clin. 46 (1996) 5-27
3. Barry M.J. Clinical practice. Prostate-specific-antigen testing for early diagnosis of prostate cancer. N. Engl. J. Med. 344 (2001) 1373-1377
4. Moul J.W. Prostate specific antigen only progression of prostate cancer. J. Urol. 163 (2000) 1632-1642
5. de la Taille A., Olsson C.A., Buttyan R., Benson M.C., Bagiella E., Cao Y., Burchardt M., Chopin D.K., and Katz A.E. Blood-based reverse transcriptase polymerase chain reaction assays for prostatic specific antigen: long term follow-up confirms the potential utility of this assay in identifying patients more likely to have biochemical recurrence (rising PSA) following radical prostatectomy. Int. J. Cancer 84 (1999) 360-364
6. Elkord E., Williams P.E., Kynaston H., and Rowbottom A.W. Differential CTLs specific for prostate-specific antigen in healthy donors and patients with prostate cancer. Int. Immunol. 17 10 (2005) 1315-1325
7. Latza U., Niedobitek G., Schwarting R., Nekarda H., and Stein H. Ber-EP4: new monoclonal antibody which distinguishes epithelia from mesothelial. J. Clin. Pathol. 43 (1990) 213-219
8. Gaffey M.J., Mills S.E., Swanson P.E., Zarbo R.J., Shah A.R., and Wick M.R. Immunoreactivity for BER-EP4 in adenocarcinomas, adenomatoid tumors, and malignant mesotheliomas. Am. J. Surg. Pathol. 16 (1992) 593-599
9. Gleason D.F., and Mellinger G.T. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J. Urol. 111 (1994) 58-64
10. Eaton M.C., Hardingham J.E., Kotasek D., and Dobrovic A. Immunobead RT-PCR: a sensitive method for detection of circulating tumor cells. BioTechniques 22 (1997) 100-105
11. Makarovskiy A.N., Ackerley III W., Wojcik L., Halpert G.K., Stein B.S., Carreiro M.P., and Hixson D.C. Application of immunomagnetic beads in combination with RT-PCR for the detection of circulating prostate cancer cells. J. Clin. Lab. Anal. 11 (1997) 346-350
12. Ghossein R.A., Osman I., Bhattacharya S., Ferrara J., Fazzari M., Cordon-Cardo C., and Scher H.I. Detection of prostatic specific membrane antigen messenger RNA using immunobead reverse transcriptase polymerase chain reaction. Diagn. Mol. Pathol. 8 (1999) 59-65
13. Hardingham J.E., Kotasek D., Farmer B., Butler R.N., Mi J.X., Sage R.E., and Dobrovic A. Immunobead-PCR: a technique for the detection of circulating tumor cells using immunomagnetic beads and the polymerase chain reaction. Cancer Res. 53 (1993) 3455-3458
14. Olsson C.A., De Vries G.M., Buttyan R., and Katz A.E. Reverse transcriptase-polymerase chain reaction assays for prostate cancer. Urol. Clin. North Am. 24 (1997) 367-378
15. Ghossein R.A., Bhattacharya S., and Rosai J. Molecular detection of micrometastases and circulating tumor cells in solid tumors. Clin. Cancer Res. 5 (1999) 1950-1960
16. Halabi S., Small E.J., Hayes D.F., Vogelzang N.J., and Kantoff P.W. Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in metastatic prostate cancer: a nested study within CALGB 9583. J. Clin. Oncol. 21 (2003) 490-495
17. Fong L., Hou Y., Rivas A., Benike C., Yuen A., Fisher G.A., Davis M.M., and Engleman E.G. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 8809-8814
18. Harper M.E., Wilson D.W., Jensen H.M., Pierrepoint C.G., and Griffiths K. Steroid hormone concentrations in relation to patient prognosis and prostate tumor grade. J. Steroid Biochem. 27 (1987) 521-524
19. Robinson M.R., and Thomas B.S. Effect of hormonal therapy on plasma testosterone levels in prostatic carcinoma. Br. Med. J. 4 (1971) 391-394
20. Chen S.S., Chen K.K., Lin A.T., Chang Y.H., Wu H.H., and Chang L.S. The correlation between pretreatment serum hormone levels and treatment outcome for patients with prostatic cancer and bony metastasis. B.J.U. Int. 89 (2002) 710-713